Metformin and Systemic Metabolism
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Metformin can improve patients’ hyperglycemia through significant suppression of hepatic glucose production. However, up to 300 times higher concentrations of metformin accumulate in the intestine than in the circulation, where it alters nutrient metabolism in intestinal epithelial cells and microbiome, leading to increased lactate production. Hepatocytes use lactate to make glucose at the cost of energy expenditure, creating a futile intestine-liver cycle. Furthermore, metformin reduces blood lipopolysaccharides and its initiated low-grade of inflammation and increased oxidative phosphorylation in liver and adipose tissues. These metformin effects result in the improvement of insulin sensitivity and glucose utilization in extrahepatic tissues. This review discusses the current understanding of metformin’s impact on systemic metabolism and its molecular mechanisms of action in various tissues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“reported that metformin activates AMP-activated kinase (AMPK) [31].”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases
Franceschi, C., & Campisi, J. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu057 · Cited by 3,891
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 1×
“Patients with T2D have a different composition of intestinal microbiota compared to healthy individuals, and intestinal microbial dysbiosis is associated with obesity and T2D [84, 85].”
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Fascinatingly, patients treated with metformin have reduced cancer incidence [6, 7], and metformin increases the lifespan of C.”
BackgroundImpaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes
Petersen, K. F., Dufour, S., Befroy, D., Garcia, R., & Shulman, G. I. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031314 · Cited by 2,193 · cited 1×
“Patients with T2D have decreased mitochondrial numbers and respiratory activity in the liver and other metabolic tissues, and mitochondrial dysfunction is implicated in the development of T2D [80].”
BackgroundOWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 3×
“Since supra-pharmacological metformin concentrations inhibit mitochondrial respiration in hepatocytes [15, 47, 48], this may occur in intestinal epithelial cells as well due to such high metformin concentrations.”
BackgroundDisentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 7×
“Foretz M et al. (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.”
BackgroundInfluentialWu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632
Shin, N.-R., Lee, J.-C., Lee, H.-Y., Kim, M.-S., Whon, T. W., Lee, M.-S., & Bae, J.-W. (2014) · Gut · doi:10.1136/gutjnl-2012-303839 · Cited by 1,550
Metformin improves healthspan and lifespan in mice
Martin-Montalvo, A., Mercken, E. M., Mitchell, S. J., Palacios, H. H., Mote, P. L., Scheibye-Knudsen, M., Gomes, A. P., Ward, T. M., Minor, R. K., Blouin, M.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3192 · Cited by 1,445
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 2×
“Since supra-pharmacological metformin concentrations inhibit mitochondrial respiration in hepatocytes [15, 47, 48], this may occur in intestinal epithelial cells as well due to such high metformin concentrations.”
BackgroundMetformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 1×
“In addition to activation of classical AMPK signaling, metformin can inhibit the activity of mG3PDH to increase cytoplasmic NADH levels and cytosolic redox state to mediate metformin’s antihyperglycemic effect (Figure 1, lower)[39].”
BackgroundForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 3×
“It was thus proposed that the principal mechanism of metformin action is through inhibition of mitochondrial complex 1 activity [42, 44], however, metformin is a weak inhibitor of mitochondrial complex 1 with an IC50 of 19–66 mM [78, 79].”
BackgroundMetabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 2×
“In human studies, metformin reduced gluconeogenesis in the liver by more than 33% [29, 30].”
BackgroundAMP-activated protein kinase mediates mitochondrial fission in response to energy stress
Toyama, E. Q., Herzig, S., Courchet, J., Lewis, T. L., Losón, O. C., Hellberg, K., Young, N. P., Chen, H., Polleux, F., Chan, D. C., et al. (2016) · Science · doi:10.1126/science.aab4138 · Cited by 1,085
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052 · cited 2×
“In human studies, metformin reduced gluconeogenesis in the liver by more than 33% [29, 30].”
BackgroundMetformin retards aging in C. elegans by altering microbial folate and methionine metabolism
Cabreiro, F., Au, C., Leung, K.-Y., Vergara-Irigaray, N., Cochemé, H. M., Noori, T., Weinkove, D., Schuster, E., Greene, N. D. E., & Gems, D. (2013) · Cell · doi:10.1016/j.cell.2013.02.035 · Cited by 967
Fullerton, M. D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.-P., O'Neill, H. M., Ford, R. J., Palanivel, R., O'Brien, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3372 · Cited by 893
Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2074 · Cited by 806 · cited 1×
“In an animal study, chronic metformin treatment enhanced insulin-stimulated glucose uptake in muscle, and inactivation of AMPK blunted metformin’s effect [57]; in patients, metformin increased glucose disposal and glycogen contents in skeletal muscle [58].”
BackgroundEffects of metformin and other biguanides on oxidative phosphorylation in mitochondria
Bridges, H. R., Jones, A. J. Y., Pollak, M. N., & Hirst, J. (2014) · Biochemical Journal · doi:10.1042/bj20140620 · Cited by 661 · cited 1×
“It was thus proposed that the principal mechanism of metformin action is through inhibition of mitochondrial complex 1 activity [42, 44], however, metformin is a weak inhibitor of mitochondrial complex 1 with an IC50 of 19–66 mM [78, 79].”
BackgroundMetformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Hattori, Y., Suzuki, K., Hattori, S., & Kasai, K. (2006) · Hypertension · doi:10.1161/01.hyp.0000221429.94591.72 · Cited by 487
Metformin Action: Concentrations Matter
He, L., & Wondisford, F. E. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.01.003 · Cited by 448 · cited 4×
“Metformin negatively modulates AMP deaminase to augment AMP levels [41] and AMP inhibits adenylate cyclase or FBP-1 to suppresses the HGP [42, 43], however, the metformin concentrations required to change AMP levels are ≥ 250 μM [32, 44], and these concentrations are unreachable in the portal vein under physiological…”
BackgroundInfluentialMetformin Improves Mitochondrial Respiratory Activity through Activation of AMPK
Wang, Y., An, H., Liu, T., Qin, C., Sesaki, H., Guo, S., Radovick, S., Hussain, M., Maheshwari, A., Wondisford, F. E., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.070 · Cited by 432 · cited 9×
“This metformin concentration had no inhibitory effect on the activity of each mitochondrial complex [15].”
BackgroundInfluentialSelf-citationAccumulation of Metformin by Tissues of the Normal and Diabetic Mouse
Wilcock, C., & Bailey, C. J. (1994) · Xenobiotica · doi:10.3109/00498259409043220 · Cited by 418 · cited 5×
“Circulating metformin concentrations are around 10–40 μM in animals and in humans [11, 16].”
BackgroundInfluentialMetformin Activates a Duodenal Ampk-Dependent Pathway to Lower Hepatic Glucose Production in Rats
Duca, F. A., Côté, C. D., Rasmussen, B. A., Zadeh-Tahmasebi, M., Rutter, G. A., Filippi, B. M., & Lam, T. K. T. (2015) · Nature Medicine · doi:10.1038/nm.3787 · Cited by 402
Vasamsetti, S. B., Karnewar, S., Kanugula, A. K., Thatipalli, A. R., Kumar, J. M., & Kotamraju, S. (2015) · Diabetes · doi:10.2337/db14-1225 · Cited by 397 · cited 1×
“Interestingly, suprapharmacological metformin prevents monocyte-to-macrophage differentiation via AMPK activation to reduce the production of proinflammatory cytokines and promote the macrophage polarization to anti-inflammatory functional M2 phenotypes [94].”
BackgroundBannister, C. A., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., & Currie, C. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12354 · Cited by 356
Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase
Hunter, R. W., Hughey, C. C., Lantier, L., Sundelin, E. I., Peggie, M., Zeqiraj, E., Sicheri, F., Jessen, N., Wasserman, D. H., & Sakamoto, K. (2018) · Nature Medicine · doi:10.1038/s41591-018-0159-7 · Cited by 313 · cited 15×
“the hallmark of T2D, results in increased HGP and decreased glucose utilization in extrahepatic tissues (muscle and adipose tissues), causing fasting hyperglycemia in patients with T2D.”
BackgroundInfluentialMetformin activates AMPK through the lysosomal pathway
Zhang, C.-S., Li, M., Ma, T., Zong, Y., Cui, J., Feng, J.-W., Wu, Y.-Q., Lin, S.-Y., & Lin, S.-C. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.003 · Cited by 280 · cited 1×
“Metformin stimulates the relocation of AMPK and LKB1 to the lysosomes to activate the AMPK [35].”
BackgroundDykens, J. A., Jamieson, J., Marroquin, L., Nadanaciva, S., Billis, P. A., & Will, Y. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.08.013 · Cited by 220 · cited 1×
“It was thus proposed that the principal mechanism of metformin action is through inhibition of mitochondrial complex 1 activity [42, 44], however, metformin is a weak inhibitor of mitochondrial complex 1 with an IC50 of 19–66 mM [78, 79].”
BackgroundLuo, T., Nocon, A., Fry, J., Sherban, A., Rui, X., Jiang, B., Xu, X. J., Han, J., Yan, Y., Yang, Q., et al. (2016) · Diabetes · doi:10.2337/db15-1122 · Cited by 172 · cited 1×
“It was also reported that metformin improves insulin signaling in skeletal muscle by regulating the expression of miR-2 and TGFβ/smad7; moreover, metformin-mediated activation of AMPK and suppression of TGFβ/smad3 in adipose tissues improves systemic insulin sensitivity in obese models [97].”
BackgroundMeng, S., Cao, J., He, Q., Xiong, L., Chang, E., Radovick, S., Wondisford, F. E., & He, L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.604421 · Cited by 146
Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin
Song, S., Andrikopoulos, S., Filippis, C., Thorburn, A. W., Khan, D., & Proietto, J. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.2.e275 · Cited by 122 · cited 1×
“In animal models, metformin inhibited HGP by over 60% in a euglycemic-clamp study [27] and inhibited 50% of endogenous glucose production in high-fat-diet (HFD)-fed rats [28].”
BackgroundSubcellular Distribution of Metformin in Rat Liver
Wilcock, C., Wyre, N. D., & Bailey, C. J. (1991) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1991.tb03507.x · Cited by 86 · cited 4×
“After oral ingestion, metformin concentrations in the intestinal mucosa are 30–300 times higher than in the circulation [16, 46].”
BackgroundInfluentialMetformin-Treated Patients With Type 2 Diabetes Have Normal Mitochondrial Complex I Respiration
Larsen, S., Rabøl, R., Hansen, C. N., Madsbad, S., Helge, J. W., & Dela, F. (2012) · Diabetologia · doi:10.1007/s00125-011-2340-0 · Cited by 81 · cited 1×
“Human studies revealed that metformin activates mitochondrial respiratory chain activity in tissues and cells other than intestinal epithelial cells [81, 82] and we and others found that metformin significantly increased mitochondrial complex 1 activity in the liver of mice [9, 15].”
BackgroundGlucose plus metformin compared with glucose alone on β-cell function in mouse pancreatic islets
HASHEMITABAR, M., BAHRAMZADEH, S., SAREMY, S., & NEJADDEHBASHI, F. (2015) · Biomedical Reports · doi:10.3892/br.2015.476 · Cited by 21
Cited by
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Han, Y.-C., Tang, S.-Q., Liu, Y.-T., Li, A.-M., Zhan, M., Yang, M., Song, N., Zhang, W., Wu, X.-Q., Peng, C.-H., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04184-8 · Cited by 257
Metformin decelerates aging clock in male monkeys
Yang, Y., Lu, X., Liu, N., Ma, S., Zhang, H., Zhang, Z., Yang, K., Jiang, M., Zheng, Z., Qiao, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.021 · Cited by 227
Buchynskyi, M., Kamyshna, I., Halabitska, I., Petakh, P., Kunduzova, O., Oksenych, V., & Kamyshnyi, O. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1577724 · Cited by 30
“In addition to improving glycemic control, metformin enhances SCFA production, which improves insulin sensitivity and lipid metabolism (Petakh et al., 2023c; He, 2020; Mueller et al., 2021).”
Metadata
- Authors
- He, L.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 41
- Issue
- 11
- Pages
- 868-881
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W3088392016
- Cited by
- 235
- References
- 40
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.